Zhigang Tang

Prof. Zhigang Tang

orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2022 in Carbohydrate Polymers
Verified
Journal Article
Closed access
PDPengpeng Deng
Pengpeng Deng
LYLichao Yao
Lichao Yao
JCJuanjuan Chen
Juanjuan Chen
ZTZhigang Tang
Zhigang Tang
JZJinping Zhou
Jinping Zhou

28 November 2018 in Journal of Experimental & Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
ZZZhengle Zhang
Zhengle Zhang
HHHan Han
Han Han
YRYuping Rong
Yuping Rong
KZKongfan Zhu
Kongfan Zhu
ZZZhong-Chao Zhu
Zhong-Chao Zhu
JTJing Tao
Jing Tao
Profound chemoresistance remains an intractable obstacle in pancreatic cancer treatment. Pancreatic cancer stem cells (CSCs) and the ubiquitous hypoxic niche have been proposed to account for drug resistance. However, the mechanism involved requires further exploration. This study investigated whether the hypoxic niche enhances gemcitabine-induced stemness and acquired resistance in pancreatic cancer cells by activating the AKT/Notch1 signaling cascade. The therapeutic effects of blockading this signaling cascade on gemcitabine-enriched CSCs were also investigated. The expression levels of CSC-associated markers Bmi1 and Sox2 as well as those of proteins involved in AKT/Notch1 signaling were measured by Western blot analysis. The expression level of the pancreatic CSC marker CD24 was measured by flow cytometry. Change in gemcitabine sensitivity was evaluated by the MTT assay. The ability of sphere formation was tested by the sphere-forming assay in stem cell medium. The ability of migration and invasion was detected by the transwell migration/invasion assay. A mouse xenograft model of pancreatic cancer was established to determine the effect of Notch1 inhibition on the killing effect of gemcitabine in vivo. The ability of metastasis was investigated by an in vivo lung metastasis assay. Gemcitabine promoted pancreatic cancer cell stemness and associated malignant phenotypes such as enhanced migration, invasion, metastasis, and chemoresistance. The AKT/Notch1 signaling cascade was activated after gemcitabine treatment and mediated this process. Blockading this pathway enhanced the killing effect of gemcitabine in vivo. However, supplementation with hypoxia treatment synergistically enhanced the AKT/Notch1 signaling pathway and collaboratively promoted gemcitabine-induced stemness. These findings demonstrate a novel mechanism of acquired gemcitabine resistance in pancreatic cancer cells through induction of stemness, which was mediated by the activation of AKT/Notch1 signaling and synergistically aggravated by the ubiquitous hypoxic niche. Our results might provide new insights for identifying potential targets for reversing chemoresistance in patients with pancreatic cancer.

1 December 2019 in Pancreatology
Verified
Journal Article
Closed access
WWWei Wang
Wei Wang
YHYing He
Ying He
LWLun Wu
Lun Wu
LYLin Ye
Lin Ye
LYLichao Yao
Lichao Yao
ZTZhigang Tang
Zhigang Tang

11 April 2022 in Epigenetics
Verified
Journal Article
Closed access
WWWei Wang
Wei Wang
YHYing He
Ying He
LZLu-Lu Zhai
Lu-Lu Zhai
LCLong-Jiang Chen
Long-Jiang Chen
LYLi-Chao Yao
Li-Chao Yao
JNJin zhuo Ning
Jin zhuo Ning
Pancreatic cancer (PC) is one of the most fatal cancers with a very poor prognosis. Here, we found that N6-methyladenosine (m6A) RNA demethylase fat mass and obesity-related protein (FTO) promote the growth, migration and invasion of PC. FTO expression level is increased in human PC and is associated with poor prognosis of PC patients. Knockdown of FTO increases m6A methylation of TFPI-2 mRNA in PC cells, thereby increasing mRNA stability via the m6A reader YTHDF1, resulting in up-regulation of TFPI-2 expression, and inhibits PC proliferation, colony formation, sphere formation, migration and invasion in vitro, as well as tumour growth in vivo. Rescue assay further confirms that FTO facilitates cancer progression by reducing the expression of TFPI-2. Mechanistically, FTO promotes the progression of PC at least partially through reducing m6A/YTHDF1 mediated TFPI-2 mRNA stability. Our findings reveal that FTO, as an m6A demethylase, plays a critical role in promoting PC growth, migration and invasion, suggesting that FTO may be a potential therapeutic target for treating PC.

4 August 2022 in International Journal of Oncology
Verified
Journal Article
Open access
PDF file
LCLong-Jiang Chen
Long-Jiang Chen
LWLun Wu
Lun Wu
WWWei Wang
Wei Wang
LZLu-Lu Zhai
Lu-Lu Zhai
FXFeng Xiang
Feng Xiang
ZTZhigang Tang
Zhigang Tang
Pancreatic cancer (PC) is a lethal type of cancer for which effective therapies are limited. Long non‑coding RNAs (lncRNAs) represent a critical type of regulator category, mediating the tumorigenesis and development of various tumor types, including PC. However, the expression patterns and functions of numerous lncRNAs in PC remain poorly understood. In the present study, linc01614 was identified as a PC‑related lncRNA. linc01614 was notably upregulated in PC tissues and cell lines and was associated with the poor disease‑free survival of patients with PC according to the analysis of The Cancer Genome Atlas‑derived datasets. Functionally, linc01614 knockdown suppressed PC cell proliferation, migration and invasion in vitro, and inhibited tumor proliferation in vitro and in vivo. Mechanistically, linc01614 overexpression stabilized the level of β‑catenin protein to hyperactivate the WNT/β‑catenin signaling pathway in PC cells. Further analyses revealed that linc01614 bound to GSK‑3β and perturbed the interaction between GSK‑3β and AXIN1, thereby preventing the formation of the β‑catenin degradation complex and reducing the degradation of β‑catenin. In summary, the present findings reveal that linc01614 may function as an oncogene and promote the progression of PC and may thus be considered as a potential therapeutic target in the future.

1 April 2021 in Pathology - Research and Practice
Verified
Journal Article
Closed access
LWLun Wu
Lun Wu
JZJiao Zhou
Jiao Zhou
WZWenbo Zhou
Wenbo Zhou
XHXue-Fei Huang
Xue-Fei Huang
QCQinhua Chen
Qinhua Chen
ZTZhigang Tang
Zhigang Tang